Summary
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Generic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Generic Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.
The Generic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Generic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Generic Drugs Segment by Company
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Generic Drugs Segment by Type
Prescription
Non-Prescription Drugs
Generic Drugs Segment by Application
Hospital
Clinic
Others
Generic Drugs Segment by Application
Hospital
Clinic
Others
Generic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
- Preface
- Scope of Report
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Data Source
- Secondary Sources
- Primary Sources
- Market Overview
- Product Definition
- Generic Drugs by Type
- Market Value Comparison by Type (2020 VS 2024 VS 2031)
- Prescription
- Non-Prescription Drugs
- Generic Drugs by Application
- Market Value Comparison by Application (2020 VS 2024 VS 2031)
- Hospital
- Clinic
- Others
- Assumptions and Limitations
- Generic Drugs Breakdown Data by Type
- Global Generic Drugs Historic Market Size by Type (2020-2025)
- Global Generic Drugs Forecasted Market Size by Type (2026-2031)
- Generic Drugs Breakdown Data by Application
- Global Generic Drugs Historic Market Size by Application (2020-2025)
- Global Generic Drugs Forecasted Market Size by Application (2026-2031)
- Global Growth Trends
- Global Generic Drugs Market Perspective (2020-2031)
- Global Generic Drugs Growth Trends by Region
- Global Generic Drugs Market Size by Region: 2020 VS 2024 VS 2031
- Generic Drugs Historic Market Size by Region (2020-2025)
- Generic Drugs Forecasted Market Size by Region (2026-2031)
- Generic Drugs Market Dynamics
- Generic Drugs Industry Trends
- Generic Drugs Market Drivers
- Generic Drugs Market Challenges
- Generic Drugs Market Restraints
- Market Competitive Landscape by Players
- Global Top Generic Drugs Players by Revenue
- Global Top Generic Drugs Players by Revenue (2020-2025)
- Global Generic Drugs Revenue Market Share by Players (2020-2025)
- Global Generic Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- Global Key Players of Generic Drugs Head Office and Area Served
- Global Generic Drugs Players, Product Type & Application
- Global Generic Drugs Manufacturers Established Date
- Global Generic Drugs Market CR5 and HHI
- Global Players Mergers & Acquisition
- Global Top Generic Drugs Players by Revenue
- North America
- North America Generic Drugs Market Size (2020-2031)
- North America Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- North America Generic Drugs Market Size by Country (2020-2025)
- North America Generic Drugs Market Size by Country (2026-2031)
- United States
- United States
- Canada
- Mexico
- Europe
- Europe Generic Drugs Market Size (2020-2031)
- Europe Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Europe Generic Drugs Market Size by Country (2020-2025)
- Europe Generic Drugs Market Size by Country (2026-2031)
- Germany
- France
- U.K.
- Italy
- Spain
- Russia
- Netherlands
- Nordic Countries
- Asia-Pacific
- Asia-Pacific Generic Drugs Market Size (2020-2031)
- Asia-Pacific Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Asia-Pacific Generic Drugs Market Size by Country (2020-2025)
- Asia-Pacific Generic Drugs Market Size by Country (2026-2031)
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Southeast Asia
- South America
- South America Generic Drugs Market Size (2020-2031)
- South America Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- South America Generic Drugs Market Size by Country (2020-2025)
- South America Generic Drugs Market Size by Country (2026-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Middle East & Africa
- Middle East & Africa Generic Drugs Market Size (2020-2031)
- Middle East & Africa Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Middle East & Africa Generic Drugs Market Size by Country (2020-2025)
- Middle East & Africa Generic Drugs Market Size by Country (2026-2031)
- Saudi Arabia
- Israel
- United Arab Emirates
- Turkey
- Iran
- Egypt
- Players Profiled
- Teva
- Teva Company Information
- Teva Business Overview
- Teva Revenue in Generic Drugs Business (2020-2025)
- Teva Generic Drugs Product Portfolio
- Teva Recent Developments
- Novartis - Sandoz
- Novartis - Sandoz Company Information
- Novartis - Sandoz Business Overview
- Novartis - Sandoz Revenue in Generic Drugs Business (2020-2025)
- Novartis - Sandoz Generic Drugs Product Portfolio
- Novartis - Sandoz Recent Developments
- Mylan
- Mylan Company Information
- Mylan Business Overview
- Mylan Revenue in Generic Drugs Business (2020-2025)
- Mylan Generic Drugs Product Portfolio
- Mylan Recent Developments
- Sun Pharmaceutical
- Sun Pharmaceutical Company Information
- Sun Pharmaceutical Business Overview
- Sun Pharmaceutical Revenue in Generic Drugs Business (2020-2025)
- Sun Pharmaceutical Generic Drugs Product Portfolio
- Sun Pharmaceutical Recent Developments
- Aspen
- Aspen Company Information
- Aspen Business Overview
- Aspen Revenue in Generic Drugs Business (2020-2025)
- Aspen Generic Drugs Product Portfolio
- Aspen Recent Developments
- Fresenius Kabi
- Fresenius Kabi Company Information
- Fresenius Kabi Business Overview
- Fresenius Kabi Revenue in Generic Drugs Business (2020-2025)
- Fresenius Kabi Generic Drugs Product Portfolio
- Fresenius Kabi Recent Developments
- Pfizer (Hospira)
- Pfizer (Hospira) Company Information
- Pfizer (Hospira) Business Overview
- Pfizer (Hospira) Revenue in Generic Drugs Business (2020-2025)
- Pfizer (Hospira) Generic Drugs Product Portfolio
- Pfizer (Hospira) Recent Developments
- Sanofi
- Sanofi Company Information
- Sanofi Business Overview
- Sanofi Revenue in Generic Drugs Business (2020-2025)
- Sanofi Generic Drugs Product Portfolio
- Sanofi Recent Developments
- Aurobindo
- Aurobindo Company Information
- Aurobindo Business Overview
- Aurobindo Revenue in Generic Drugs Business (2020-2025)
- Aurobindo Generic Drugs Product Portfolio
- Aurobindo Recent Developments
- Lupin
- Lupin Company Information
- Lupin Business Overview
- Lupin Revenue in Generic Drugs Business (2020-2025)
- Lupin Generic Drugs Product Portfolio
- Lupin Recent Developments
- Dr. Reddy's
- Dr. Reddy's Company Information
- Dr. Reddy's Business Overview
- Dr. Reddy's Revenue in Generic Drugs Business (2020-2025)
- Dr. Reddy's Generic Drugs Product Portfolio
- Dr. Reddy's Recent Developments
- Apotex
- Apotex Company Information
- Apotex Business Overview
- Apotex Revenue in Generic Drugs Business (2020-2025)
- Apotex Generic Drugs Product Portfolio
- Apotex Recent Developments
- Cipla
- Cipla Company Information
- Cipla Business Overview
- Cipla Revenue in Generic Drugs Business (2020-2025)
- Cipla Generic Drugs Product Portfolio
- Cipla Recent Developments
- ENDO (Par Pharmaceutical)
- ENDO (Par Pharmaceutical) Company Information
- ENDO (Par Pharmaceutical) Business Overview
- ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2020-2025)
- ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
- ENDO (Par Pharmaceutical) Recent Developments
- Stada Arzneimittel
- Stada Arzneimittel Company Information
- Stada Arzneimittel Business Overview
- Stada Arzneimittel Revenue in Generic Drugs Business (2020-2025)
- Stada Arzneimittel Generic Drugs Product Portfolio
- Stada Arzneimittel Recent Developments
- Krka Group
- Krka Group Company Information
- Krka Group Business Overview
- Krka Group Revenue in Generic Drugs Business (2020-2025)
- Krka Group Generic Drugs Product Portfolio
- Krka Group Recent Developments
- Nichi-Iko Pharmaceutical
- Nichi-Iko Pharmaceutical Company Information
- Nichi-Iko Pharmaceutical Business Overview
- Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2020-2025)
- Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
- Nichi-Iko Pharmaceutical Recent Developments
- Valeant
- Valeant Company Information
- Valeant Business Overview
- Valeant Revenue in Generic Drugs Business (2020-2025)
- Valeant Generic Drugs Product Portfolio
- Valeant Recent Developments
- Zydus Cadila
- Zydus Cadila Company Information
- Zydus Cadila Business Overview
- Zydus Cadila Revenue in Generic Drugs Business (2020-2025)
- Zydus Cadila Generic Drugs Product Portfolio
- Zydus Cadila Recent Developments
- Hikma
- Hikma Company Information
- Hikma Business Overview
- Hikma Revenue in Generic Drugs Business (2020-2025)
- Hikma Generic Drugs Product Portfolio
- Hikma Recent Developments
- Pharmaniaga Berhad
- Pharmaniaga Berhad Company Information
- Pharmaniaga Berhad Business Overview
- Pharmaniaga Berhad Revenue in Generic Drugs Business (2020-2025)
- Pharmaniaga Berhad Generic Drugs Product Portfolio
- Pharmaniaga Berhad Recent Developments
- Hovid Berhad
- Hovid Berhad Company Information
- Hovid Berhad Business Overview
- Hovid Berhad Revenue in Generic Drugs Business (2020-2025)
- Hovid Berhad Generic Drugs Product Portfolio
- Hovid Berhad Recent Developments
- Duopharma Biotech
- Duopharma Biotech Company Information
- Duopharma Biotech Business Overview
- Duopharma Biotech Revenue in Generic Drugs Business (2020-2025)
- Duopharma Biotech Generic Drugs Product Portfolio
- Duopharma Biotech Recent Developments
- Kotra Pharma
- Kotra Pharma Company Information
- Kotra Pharma Business Overview
- Kotra Pharma Revenue in Generic Drugs Business (2020-2025)
- Kotra Pharma Generic Drugs Product Portfolio
- Kotra Pharma Recent Developments
- HOE Pharmaceutical
- HOE Pharmaceutical Company Information
- HOE Pharmaceutical Business Overview
- HOE Pharmaceutical Revenue in Generic Drugs Business (2020-2025)
- HOE Pharmaceutical Generic Drugs Product Portfolio
- HOE Pharmaceutical Recent Developments
- Y.S.P. Industries
- Y.S.P. Industries Company Information
- Y.S.P. Industries Business Overview
- Y.S.P. Industries Revenue in Generic Drugs Business (2020-2025)
- Y.S.P. Industries Generic Drugs Product Portfolio
- Y.S.P. Industries Recent Developments
- Teva
- Report Conclusion
- Disclaimer
List of Tables
| Table 1 | :Secondary Sources |
| Table 2 | :Primary Sources |
| Table 3 | :Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 4 | :Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 5 | :Global Generic Drugs Market Size by Type (2020-2025) & (US$ Million) |
| Table 6 | :Global Generic Drugs Revenue Market Share by Type (2020-2025) |
| Table 7 | :Global Generic Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million) |
| Table 8 | :Global Generic Drugs Revenue Market Share by Type (2026-2031) |
| Table 9 | :Global Generic Drugs Market Size by Application (2020-2025) & (US$ Million) |
| Table 10 | :Global Generic Drugs Revenue Market Share by Application (2020-2025) |
| Table 11 | :Global Generic Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million) |
| Table 12 | :Global Generic Drugs Revenue Market Share by Application (2026-2031) |
| Table 13 | :Global Generic Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031 |
| Table 14 | :Global Generic Drugs Market Size by Region (2020-2025) & (US$ Million) |
| Table 15 | :Global Generic Drugs Market Share by Region (2020-2025) |
| Table 16 | :Global Generic Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million) |
| Table 17 | :Global Generic Drugs Market Share by Region (2026-2031) |
| Table 18 | :Generic Drugs Industry Trends |
| Table 19 | :Generic Drugs Industry Drivers |
| Table 20 | :Generic Drugs Industry Opportunities and Challenges |
| Table 21 | :Generic Drugs Market Restraints |
| Table 22 | :Global Top Generic Drugs Players by Revenue (US$ Million) & (2020-2025) |
| Table 23 | :Global Generic Drugs Revenue Market Share by Players (2020-2025) |
| Table 24 | :Global Generic Drugs Industry Players Ranking, 2023 VS 2024 VS 2025 |
| Table 25 | :Global Key Players of Generic Drugs, Headquarters and Area Served |
| Table 26 | :Global Generic Drugs Players, Product Type & Application |
| Table 27 | :Global Players Market Concentration Ratio (CR5 and HHI) |
| Table 28 | :Global Generic Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
| Table 29 | :Players Mergers & Acquisitions, Expansion Plans |
| Table 30 | :North America Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 31 | :North America Generic Drugs Market Size by Country (2020-2025) & (US$ Million) |
| Table 32 | :North America Generic Drugs Market Size by Country (2026-2031) & (US$ Million) |
| Table 33 | :Europe Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 34 | :Europe Generic Drugs Market Size by Country (2020-2025) & (US$ Million) |
| Table 35 | :Europe Generic Drugs Market Size by Country (2026-2031) & (US$ Million) |
| Table 36 | :Asia Pacific Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 37 | :Asia Pacific Generic Drugs Market Size by Region (2020-2025) & (US$ Million) |
| Table 38 | :Asia Pacific Generic Drugs Market Size by Country (2026-2031) & (US$ Million) |
| Table 39 | :South America Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 40 | :South America Generic Drugs Market Size by Country (2020-2025) & (US$ Million) |
| Table 41 | :South America Generic Drugs Market Size by Country (2026-2031) & (US$ Million) |
| Table 42 | :Middle East & Africa Generic Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 43 | :Middle East & Africa Generic Drugs Market Size by Country (2020-2025) & (US$ Million) |
| Table 44 | :Middle East & Africa Generic Drugs Market Size by Country (2026-2031) & (US$ Million) |
| Table 45 | :Teva Company Information |
| Table 46 | :Teva Business Overview |
| Table 47 | :Teva Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 48 | :Teva Generic Drugs Product Portfolio |
| Table 49 | :Teva Recent Developments |
| Table 50 | :Novartis - Sandoz Company Information |
| Table 51 | :Novartis - Sandoz Business Overview |
| Table 52 | :Novartis - Sandoz Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 53 | :Novartis - Sandoz Generic Drugs Product Portfolio |
| Table 54 | :Novartis - Sandoz Recent Developments |
| Table 55 | :Mylan Company Information |
| Table 56 | :Mylan Business Overview |
| Table 57 | :Mylan Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 58 | :Mylan Generic Drugs Product Portfolio |
| Table 59 | :Mylan Recent Developments |
| Table 60 | :Sun Pharmaceutical Company Information |
| Table 61 | :Sun Pharmaceutical Business Overview |
| Table 62 | :Sun Pharmaceutical Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 63 | :Sun Pharmaceutical Generic Drugs Product Portfolio |
| Table 64 | :Sun Pharmaceutical Recent Developments |
| Table 65 | :Aspen Company Information |
| Table 66 | :Aspen Business Overview |
| Table 67 | :Aspen Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 68 | :Aspen Generic Drugs Product Portfolio |
| Table 69 | :Aspen Recent Developments |
| Table 70 | :Fresenius Kabi Company Information |
| Table 71 | :Fresenius Kabi Business Overview |
| Table 72 | :Fresenius Kabi Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 73 | :Fresenius Kabi Generic Drugs Product Portfolio |
| Table 74 | :Fresenius Kabi Recent Developments |
| Table 75 | :Pfizer (Hospira) Company Information |
| Table 76 | :Pfizer (Hospira) Business Overview |
| Table 77 | :Pfizer (Hospira) Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 78 | :Pfizer (Hospira) Generic Drugs Product Portfolio |
| Table 79 | :Pfizer (Hospira) Recent Developments |
| Table 80 | :Sanofi Company Information |
| Table 81 | :Sanofi Business Overview |
| Table 82 | :Sanofi Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 83 | :Sanofi Generic Drugs Product Portfolio |
| Table 84 | :Sanofi Recent Developments |
| Table 85 | :Aurobindo Company Information |
| Table 86 | :Aurobindo Business Overview |
| Table 87 | :Aurobindo Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 88 | :Aurobindo Generic Drugs Product Portfolio |
| Table 89 | :Aurobindo Recent Developments |
| Table 90 | :Lupin Company Information |
| Table 91 | :Lupin Business Overview |
| Table 92 | :Lupin Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 93 | :Lupin Generic Drugs Product Portfolio |
| Table 94 | :Lupin Recent Developments |
| Table 95 | :Dr. Reddy's Company Information |
| Table 96 | :Dr. Reddy's Business Overview |
| Table 97 | :Dr. Reddy's Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 98 | :Dr. Reddy's Generic Drugs Product Portfolio |
| Table 99 | :Dr. Reddy's Recent Developments |
| Table 100 | :Apotex Company Information |
| Table 101 | :Apotex Business Overview |
| Table 102 | :Apotex Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 103 | :Apotex Generic Drugs Product Portfolio |
| Table 104 | :Apotex Recent Developments |
| Table 105 | :Cipla Company Information |
| Table 106 | :Cipla Business Overview |
| Table 107 | :Cipla Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 108 | :Cipla Generic Drugs Product Portfolio |
| Table 109 | :Cipla Recent Developments |
| Table 110 | :ENDO (Par Pharmaceutical) Company Information |
| Table 111 | :ENDO (Par Pharmaceutical) Business Overview |
| Table 112 | :ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 113 | :ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio |
| Table 114 | :ENDO (Par Pharmaceutical) Recent Developments |
| Table 115 | :Stada Arzneimittel Company Information |
| Table 116 | :Stada Arzneimittel Business Overview |
| Table 117 | :Stada Arzneimittel Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 118 | :Stada Arzneimittel Generic Drugs Product Portfolio |
| Table 119 | :Stada Arzneimittel Recent Developments |
| Table 120 | :Krka Group Company Information |
| Table 121 | :Krka Group Business Overview |
| Table 122 | :Krka Group Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 123 | :Krka Group Generic Drugs Product Portfolio |
| Table 124 | :Krka Group Recent Developments |
| Table 125 | :Nichi-Iko Pharmaceutical Company Information |
| Table 126 | :Nichi-Iko Pharmaceutical Business Overview |
| Table 127 | :Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 128 | :Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio |
| Table 129 | :Nichi-Iko Pharmaceutical Recent Developments |
| Table 130 | :Valeant Company Information |
| Table 131 | :Valeant Business Overview |
| Table 132 | :Valeant Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 133 | :Valeant Generic Drugs Product Portfolio |
| Table 134 | :Valeant Recent Developments |
| Table 135 | :Zydus Cadila Company Information |
| Table 136 | :Zydus Cadila Business Overview |
| Table 137 | :Zydus Cadila Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 138 | :Zydus Cadila Generic Drugs Product Portfolio |
| Table 139 | :Zydus Cadila Recent Developments |
| Table 140 | :Hikma Company Information |
| Table 141 | :Hikma Business Overview |
| Table 142 | :Hikma Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 143 | :Hikma Generic Drugs Product Portfolio |
| Table 144 | :Hikma Recent Developments |
| Table 145 | :Pharmaniaga Berhad Company Information |
| Table 146 | :Pharmaniaga Berhad Business Overview |
| Table 147 | :Pharmaniaga Berhad Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 148 | :Pharmaniaga Berhad Generic Drugs Product Portfolio |
| Table 149 | :Pharmaniaga Berhad Recent Developments |
| Table 150 | :Hovid Berhad Company Information |
| Table 151 | :Hovid Berhad Business Overview |
| Table 152 | :Hovid Berhad Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 153 | :Hovid Berhad Generic Drugs Product Portfolio |
| Table 154 | :Hovid Berhad Recent Developments |
| Table 155 | :Duopharma Biotech Company Information |
| Table 156 | :Duopharma Biotech Business Overview |
| Table 157 | :Duopharma Biotech Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 158 | :Duopharma Biotech Generic Drugs Product Portfolio |
| Table 159 | :Duopharma Biotech Recent Developments |
| Table 160 | :Kotra Pharma Company Information |
| Table 161 | :Kotra Pharma Business Overview |
| Table 162 | :Kotra Pharma Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 163 | :Kotra Pharma Generic Drugs Product Portfolio |
| Table 164 | :Kotra Pharma Recent Developments |
| Table 165 | :HOE Pharmaceutical Company Information |
| Table 166 | :HOE Pharmaceutical Business Overview |
| Table 167 | :HOE Pharmaceutical Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 168 | :HOE Pharmaceutical Generic Drugs Product Portfolio |
| Table 169 | :HOE Pharmaceutical Recent Developments |
| Table 170 | :Y.S.P. Industries Company Information |
| Table 171 | :Y.S.P. Industries Business Overview |
| Table 172 | :Y.S.P. Industries Revenue in Generic Drugs Business (2020-2025) & (US$ Million) |
| Table 173 | :Y.S.P. Industries Generic Drugs Product Portfolio |
| Table 174 | :Y.S.P. Industries Recent Developments |
| Table 175 | :Authors List of This Report |
List of Figures
| Figure 1 | :Research Methodology |
| Figure 2 | :Research Process |
| Figure 3 | :Key Executives Interviewed |
| Figure 4 | :Generic Drugs Product Image |
| Figure 5 | :Global Generic Drugs Market Size Comparison by Type (2025-2031) & (US$ Million) |
| Figure 6 | :Global Generic Drugs Market Share by Type: 2024 VS 2031 |
| Figure 7 | :Prescription Product |
| Figure 8 | :Non-Prescription Drugs Product |
| Figure 9 | :Global Generic Drugs Market Size by Application (2025-2031) & (US$ Million) |
| Figure 10 | :Global Generic Drugs Market Share by Application: 2024 VS 2031 |
| Figure 11 | :Hospital Product |
| Figure 12 | :Clinic Product |
| Figure 13 | :Others Product |
| Figure 14 | :Global Generic Drugs Market Size (US$ Million), Year-over-Year: 2020-2031 |
| Figure 15 | :Global Generic Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031 |
| Figure 16 | :Global Generic Drugs Market Share by Region: 2024 VS 2031 |
| Figure 17 | :Global Generic Drugs Market Share by Players in 2024 |
| Figure 18 | :Global Generic Drugs Manufacturers Established Date |
| Figure 19 | :Global Top 5 and 10 Generic Drugs Players Market Share by Revenue in 2024 |
| Figure 20 | :Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
| Figure 21 | :North America Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 22 | :North America Generic Drugs Market Share by Country (2020-2031) |
| Figure 23 | :United States Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 24 | :Canada Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 25 | :Mexico Generic Drugs Market Share by Country (2020-2031) |
| Figure 26 | :Europe Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 27 | :Europe Generic Drugs Market Share by Country (2020-2031) |
| Figure 28 | :Germany Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 29 | :France Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 30 | :U.K. Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 31 | :Italy Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 32 | :Spain Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 33 | :Russia Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 34 | :Netherlands Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 35 | :Nordic Countries Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 36 | :Asia-Pacific Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 37 | :Asia-Pacific Generic Drugs Market Share by Country (2020-2031) |
| Figure 38 | :China Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 39 | :Japan Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 40 | :South Korea Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 41 | :India Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 42 | :India Generic Drugs Market Share by Country (2020-2031) |
| Figure 43 | :Australia Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 44 | :China Taiwan Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 45 | :Southeast Asia Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 46 | :South America Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 47 | :South America Generic Drugs Market Share by Country (2020-2031) |
| Figure 48 | :Brazil Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 49 | :Argentina Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 50 | :Chile Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 51 | :Colombia Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 52 | :Peru Generic Drugs Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 53 | :Teva Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 54 | :Novartis - Sandoz Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 55 | :Mylan Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 56 | :Sun Pharmaceutical Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 57 | :Aspen Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 58 | :Fresenius Kabi Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 59 | :Pfizer (Hospira) Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 60 | :Sanofi Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 61 | :Aurobindo Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 62 | :Lupin Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 63 | :Dr. Reddy's Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 64 | :Apotex Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 65 | :Cipla Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 66 | :ENDO (Par Pharmaceutical) Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 67 | :Stada Arzneimittel Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 68 | :Krka Group Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 69 | :Nichi-Iko Pharmaceutical Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 70 | :Valeant Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 71 | :Zydus Cadila Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 72 | :Hikma Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 73 | :Pharmaniaga Berhad Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 74 | :Hovid Berhad Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 75 | :Duopharma Biotech Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 76 | :Kotra Pharma Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 77 | :HOE Pharmaceutical Revenue Growth Rate in Generic Drugs Business (2020-2025) |
| Figure 78 | :Y.S.P. Industries Revenue Growth Rate in Generic Drugs Business (2020-2025) |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Generic Drugs Industry Research Report 2025
Pages: 143
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.